EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated computational-based design of putative dual TrkA/TrkB agonists for Alzheimer’s disease: pharmacophore modelling, docking, MM/GBSA, DFT and dynamics studies

A Vignesh Pandi, Vishnu Malakar, Jeyaram Bharathi Jeyabalan, Megha Sanjai, Krishna Shevate, Kalirajan Rajagopal, B R Prashantha Kumar, Antony Justin

Frontiers in Bioinformatics · 01.06.2026 · 6

DOI: 10.3389/fbinf.2026.1779769 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioinformatics, online erschienen am 01.06.2026. Verfasst von A Vignesh Pandi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Neuropharmacology and Experimental Neuroscience, Department of Pharmacology, JSS Academy of Higher Education and Research, JSS College of …. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The rapid progression of Alzheimer’s disease (AD) is primarily caused by compromised neurotrophin functions and decreased tropomyosin receptor kinase expression in the basal forebrain area. The two main pathogenic features of AD are cholinergic-dependent cognitive dysfunctions and amyloidogenic-induced neurodegeneration. Concurrent stimulation of major neurotrophin signalling pathways, such as tropomyosin receptor kinases receptor A and B (TrkA and TrkB), may reduce amyloid-β-mediated neurotoxicity and cholinergic denervation in the basal forebrain, improving cognitive performance and re-establishing neuronal communication. The development of new medications with dual agonist action towards TrkA and B receptors holds enormous therapeutic potential for managing the symptoms of neurodegenerative diseases.

Aim

This study aims to develop novel dual TrkA/TrkB receptor agonists for the treatment of AD by enhancing neurotrophin signalling, reducing cholinergic denervation, and mitigating amyloid-β-induced neurotoxicity.

Methods

An in silico drug discovery pipeline was employed, involving homology and pharmacophore modelling of amitriptyline, virtual screening of ChEMBL compounds, molecular docking, ADMET, MM/GBSA analysis, DFT calculations and molecular dynamics (MD) simulations for 100 and 300 ns to assess ligand stability and binding behaviour of the ligand–protein complexes.

Results

Six novel optimised quinoline analogues (OP-1 to OP-6) were identified as computationally predicted dual TrkA/TrkB agonists by molecular docking (−8.90 to −5.07 kcal/mol), MM/GBSA (−40.47 to −30.71 kcal/mol), ADMET and DFT analysis. Furthermore, OP-1, OP-2, and OP-3 exhibit stable binding interactions over 300 ns of MD simulations. The optimised compounds demonstrated favorable computational binding profiles, predicted pharmacokinetic properties, and stable receptor–ligand interactions, identifying them as promising candidates for further experimental validation as potential dual TrkA/TrkB modulators in Alzheimer’s disease.

Schlagwörter

Stichwörter der Autor:innen

DFT analysisTrkB homology modellingdrug designmolecular dynamicspharmacophore modelling

Autor:innen und Institutionen

  • Centre for Neuropharmacology and Experimental Neuroscience, Department of Pharmacology, JSS Academy of Higher Education and Research, JSS College of Pharmacy, Ooty, Tamil Nadu, India.
  • Department of Pharmacognosy, JSS Academy of Higher Education and Research, JSS College of Pharmacy, Ooty, Tamil Nadu, India.
  • Department of Pharmaceutical Chemistry, JSS Academy of Higher Education and Research, JSS College of Pharmacy, Ooty, Tamil Nadu, India.
  • Department of Pharmaceutical Chemistry, JSS Academy of Higher Education and Research, JSS College of Pharmacy, Mysuru, Karnataka, India.

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Vignesh Pandi, A., Malakar, V., Jeyabalan, J. B., Sanjai, M., Shevate, K., Rajagopal, K., Prashantha Kumar, B. R., & Justin, A. (2026). Integrated computational-based design of putative dual TrkA/TrkB agonists for Alzheimer’s disease: pharmacophore modelling, docking, MM/GBSA, DFT and dynamics studies. Frontiers in Bioinformatics, 6. https://doi.org/10.3389/fbinf.2026.1779769

Vancouver

Vignesh Pandi A, Malakar V, Jeyabalan JB, Sanjai M, Shevate K, Rajagopal K, et al. Integrated computational-based design of putative dual TrkA/TrkB agonists for Alzheimer’s disease: pharmacophore modelling, docking, MM/GBSA, DFT and dynamics studies. Frontiers in Bioinformatics. 2026;6. doi:10.3389/fbinf.2026.1779769

BibTeX
@article{VigneshPandi2026,
  author = {Vignesh Pandi, A and Malakar, Vishnu and Jeyabalan, Jeyaram Bharathi and Sanjai, Megha and Shevate, Krishna and Rajagopal, Kalirajan and Prashantha Kumar, B R and Justin, Antony},
  title = {Integrated computational-based design of putative dual TrkA/TrkB agonists for Alzheimer’s disease: pharmacophore modelling, docking, MM/GBSA, DFT and dynamics studies},
  journal = {Frontiers in Bioinformatics},
  year = {2026},
  volume = {6},
  doi = {10.3389/fbinf.2026.1779769}
}
Kostenlos starten →